title: [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
authors.affiliation: Horten-Zentrum für praxisorientierte Forschung und Wissenstransfer, Universitätsspital Zürich.
authors.forename: Johann
authors.initials: J
authors.lastname: Steurer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data*; D065427:Factor Xa Inhibitors; D006801:Humans; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013923:Thromboembolism / Q000191:economics / Q000209:etiology* / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014859:Warfarin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014812:Vitamin K; D014859:Warfarin; D013917:Thrombin